JP6280560B2 - 三環式インドール誘導体の結晶化プロセス - Google Patents

三環式インドール誘導体の結晶化プロセス Download PDF

Info

Publication number
JP6280560B2
JP6280560B2 JP2015544462A JP2015544462A JP6280560B2 JP 6280560 B2 JP6280560 B2 JP 6280560B2 JP 2015544462 A JP2015544462 A JP 2015544462A JP 2015544462 A JP2015544462 A JP 2015544462A JP 6280560 B2 JP6280560 B2 JP 6280560B2
Authority
JP
Japan
Prior art keywords
formula
compound
hydrogen
alkyl
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015544462A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016507477A5 (enExample
JP2016507477A (ja
Inventor
ニルセン，ソンドレ
バラジ，スリナス・バラジ・アラリカッティ・プラフラダシャール
モッカパティ，ウママヘシュワー・ピー
カダヴィルパランプ・モハメッド，アフサル・ムハンマド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1300647.3A external-priority patent/GB201300647D0/en
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of JP2016507477A publication Critical patent/JP2016507477A/ja
Publication of JP2016507477A5 publication Critical patent/JP2016507477A5/ja
Application granted granted Critical
Publication of JP6280560B2 publication Critical patent/JP6280560B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
JP2015544462A 2012-11-30 2013-11-28 三環式インドール誘導体の結晶化プロセス Active JP6280560B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN3689/DEL/2012 2012-11-30
IN3689DE2012 2012-11-30
GB1300647.3 2013-01-15
GBGB1300647.3A GB201300647D0 (en) 2013-01-15 2013-01-15 Crystallization
PCT/EP2013/074986 WO2014083113A1 (en) 2012-11-30 2013-11-28 Crystallization process of tricyclic indole derivatives

Publications (3)

Publication Number Publication Date
JP2016507477A JP2016507477A (ja) 2016-03-10
JP2016507477A5 JP2016507477A5 (enExample) 2017-12-07
JP6280560B2 true JP6280560B2 (ja) 2018-02-14

Family

ID=54266915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015544462A Active JP6280560B2 (ja) 2012-11-30 2013-11-28 三環式インドール誘導体の結晶化プロセス

Country Status (12)

Country Link
US (1) US10709798B2 (enExample)
EP (1) EP2943195A1 (enExample)
JP (1) JP6280560B2 (enExample)
KR (1) KR20150088802A (enExample)
CN (2) CN104837489A (enExample)
AU (1) AU2013351152A1 (enExample)
BR (1) BR112015012138A2 (enExample)
CA (1) CA2892485A1 (enExample)
IN (1) IN2015DN03978A (enExample)
MX (1) MX2015006871A (enExample)
RU (1) RU2015118217A (enExample)
WO (1) WO2014083113A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2015118217A (ru) 2012-11-30 2017-01-11 ДжиИ ХЕЛТКЕР ЛИМИТЕД Способ кристаллизации трициклических индольных производных
US20160144477A1 (en) * 2014-11-21 2016-05-26 Diane Scott Coated compressive subpad for chemical mechanical polishing

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177440B1 (en) * 1996-10-30 2001-01-23 Eli Lilly And Company Substituted tricyclics
CA2310250A1 (en) 1997-11-14 1999-05-27 August Masaru Watanabe Treatment for alzheimer's disease
DZ2769A1 (fr) 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
JP2005527466A (ja) 2001-08-09 2005-09-15 イーライ・リリー・アンド・カンパニー ｓＰＬＡ２インヒビターとしてのシクロヘプトＢインドール誘導体
WO2003014082A1 (en) 2001-08-09 2003-02-20 Eli Lilly And Company Cyclopenta ` b ! indole derivatives as spla2 inhibitors
GB0905328D0 (en) * 2009-03-27 2009-05-13 Ge Healthcare Ltd Indole derivatives
SG183837A1 (en) * 2010-03-26 2012-10-30 Ge Healthcare Ltd Tricyclic indole derivatives as pbr ligands
GB201016038D0 (en) 2010-09-24 2010-11-10 Ge Healthcare Ltd In vivo imaging method
GB201016411D0 (en) * 2010-09-30 2010-11-10 Ge Healthcare Ltd In vivo imaging method for cancer
GB201021263D0 (en) 2010-12-15 2011-01-26 Ge Healthcare Ltd Solid phase extraction method
US9220795B2 (en) * 2011-09-22 2015-12-29 Ge Healthcare Limited Indole derivatives
RU2015118217A (ru) 2012-11-30 2017-01-11 ДжиИ ХЕЛТКЕР ЛИМИТЕД Способ кристаллизации трициклических индольных производных

Also Published As

Publication number Publication date
BR112015012138A2 (pt) 2017-07-11
WO2014083113A1 (en) 2014-06-05
KR20150088802A (ko) 2015-08-03
EP2943195A1 (en) 2015-11-18
RU2015118217A (ru) 2017-01-11
CN111362863A (zh) 2020-07-03
AU2013351152A1 (en) 2015-05-21
CA2892485A1 (en) 2014-06-05
US20150335766A1 (en) 2015-11-26
MX2015006871A (es) 2015-09-16
CN104837489A (zh) 2015-08-12
US10709798B2 (en) 2020-07-14
IN2015DN03978A (enExample) 2015-10-02
JP2016507477A (ja) 2016-03-10

Similar Documents

Publication Publication Date Title
KR102137348B1 (ko) 시트레이트 완충제 내 18ｆ―플루시클로빈 조성물
CN101678129B (zh) 用于ccr5体内成像的放射性pet试剂
US20240217974A1 (en) Isoquinolone compound and use thereof
RU2512288C2 (ru) Производные индола, подходящие для визуализации нейровоспаления
JP5597835B2 (ja) イメージング剤及びプローブとしてのフルオロアルキルテトラベナジンカルビノール化合物
JP6280560B2 (ja) 三環式インドール誘導体の結晶化プロセス
KR20140076575A (ko) 18ｆ―표지된 생분자의 합성 방법
JP5787873B2 (ja) インビボイメージング用の放射性標識ピリジニル誘導体
US20120189547A1 (en) [18f] labelled analogues of flumazenil as in vivo imaging agents
JP5870031B2 (ja) 自動化放射合成
JP6446268B2 (ja) クエン酸緩衝液中の１８ｆ−フルシクロビン組成物
CN103415304B (zh) 生产F-18标记的β-淀粉样蛋白配体的方法
US20140288317A1 (en) Aryloxyanilide imaging agents
JP7284490B2 (ja) モノアミンオキシダーゼｂイメージングプローブ
US20160022845A1 (en) Synthon composition
EP2736898A1 (en) 5ht1a antagonist useful for in vivo imaging
EA025823B1 (ru) Способ получения f-18 меченых лигандов бета-амилоида

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171026

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20171026

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171226

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180119

R150 Certificate of patent or registration of utility model

Ref document number: 6280560

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250